Skip to Content
Søk Menu

ECTRIMS 2024: New Data Has the Potential to Paving the Way for More Personalised and Effective Treatment Plans

A study presented at ECTRIMS 2024 has identified key biomarkers that can accurately predict disability progression in multiple sclerosis (MS). These findings have the potential to significantly impact MS treatment approaches, enabling the development of more personalized and effective therapeutic strategies tailored to individual patient profiles. 

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Oceans of Hope Project Gives Patients with MS Higher Quality of Life

/ Mikkel Anthonisen
ECTRIMS24MS Play the Video 02:51
Ulrik Dalgas

Exercise is Essential for Maximizing Cognitive and Physical Functions for Individuals with MS

/ Ulrik Dalgas
ECTRIMS24MS Play the Video 01:47
Lars Hvid

Long-Term Positive Effects on Fatigue in Persons with MS

/ Lars Hvid
ECTRIMS24 Play the Video 2:20
Marie Lynning

Low Health Literacy is Associated with Lower Levels of Education, Progressive Disease Types and Higher Disease Severity in MS

/ Marie Lynning
ECTRIMS24MS Play the Video 05:20
Melinda Magyari

Patients with Secondary Progressive MS Have a Higher Mortality than Those with Primary Progressive MS

/ Melinda Magyari
ECTRIMS24MS Play the Video 03:41

Earlier Access to Effective Treatments for Children with MS Reduces the Burden of Long-Term Disability

/ Jan Andreasen
ECTRIMS24MS

ECTRIMS 2024: The World’s Largest MS Congress in Copenhagen 

/ BestPractice Nordic
ECTRIMS24MS
Melinda Magyari

Vaccinations Do Not Increase the Risk of Relapses in Multiple Sclerosis

/ Melinda Magyari
EAN24MS Play the Video 2:46

COVID-19 Vaccination and MS Relapses: Danish National Registry Insights

/ Dominika Stastna
COVID-19MS
Back to top